Manganese-Based Prussian Blue Nanocatalysts Suppress Non-Small Cell Lung Cancer Growth and Metastasis via Photothermal and Chemodynamic Therapy

Abstract

Based on the safety of prussian blue (PB) in biomedical application, we prepared manganese-based prussian blue (MnPB) nanocatalysts to achieve enhanced photothermal therapy and chemodynamic therapy. And we conducted a series of experiments to explore the therapeutic effects of MnPB nanoparticles (NPs) on non-small cell lung cancer (NSCLC) in vivo and in vitro. For in vitro experiments, the MnPB NPs suppressed growth of A549 cells by reactive oxygen species upregulation and near-infrared irradiation. Moreover, the MnPB NPs could inhibit lung cancer metastasis through downregulating the matrix metalloproteinase (MMP)-2 and MMP-9 expression in A549 cells. And for in vivo experiments, the MnPB NPs inhibited the growth of xenografted tumor effectively and were biologically safe. Meanwhile, Mn2+ as a T1-weighted agent could realize magnetic resonance imaging-guided diagnosis and treatment. To sum up, the results in this study clearly demonstrated that the MnPB NPs had remarkable effects for inhibiting the growth and metastasis of NSCLC and might serve as a promising multifunctional nanoplatform for NSCLC treatment.

Manganese-based Prussian blue nanoparticles inhibit tumor proliferation and migration via the MAPK pathway in pancreatic cancer

“…The results demonstrated that MMP2 and MMP9 decreased compared with the control group ( Figure 4C ). These results were consistent with the study published previously ( Fang et al, 2022 ). Overall, these results indicated that MnPB NPs could inhibit migration of PANC-1 cells.…”

The multifunctional Prussian blue/graphitic carbon nitride nanocomposites for fluorescence imaging-guided photothermal and photodynamic combination therapy

“…The η of PBCN was calculated to be 60.1% based on the cooling curve (Fig. 3e), which is superior to other PBNPs-based nanocomposites, such as CDs/PBNPs nanomaterials (30%), 26 MnPB NPs nanomaterials (27.8%), 11 and CaP&PB (40.2%). 28 The good photothermal stability was verified by exposing PBNC to an 808 nm laser for 5 min, followed by natural cooling to room temperature.…”

“…7 PTT is a typical treatment that induces tumor cell apoptosis via a photothermal agent irradiated under NIR light to generate local high thermal energy. 8 Common photothermal agents include gold nanomaterials, 9 MoS 2 , 10 and graphene oxide et al, 11 which have disadvantages such as high cost, complex synthesis, and low photothermal conversion efficiency. In contrast, Prussian blue nanoparticles (PBNPs) have been widely applied in PTT because of their simple synthesis, good photothermal properties, and low cytotoxicity.…”

Cypate‐loaded hollow mesoporous Prussian blue nanoparticle/hydrogel system for efficient photodynamic therapy/photothermal therapy dual‐modal antibacterial therapy

“…21 Prussian blue nanoparticles (PBs) show unique properties. 22,23 They can be synthesized in mild conditions and have an excellent light-to-heat conversion rate, which is an ideal carrier of Cy for PDT/PTT synergistic therapy. 24 In addition, due to its outstanding biocompatibility, PB has been approved by the FDA.…”

“…We hypothesize that co‐delivery of the Cy with the photothermal agent (PTA) NPs can achieve the combined PDT and PTT, which could activation by one NIR light irradiation and integrate more functions 21 . Prussian blue nanoparticles (PBs) show unique properties 22,23 . They can be synthesized in mild conditions and have an excellent light‐to‐heat conversion rate, which is an ideal carrier of Cy for PDT/PTT synergistic therapy 24 .…”